3 documents found, page 1 of 1
Impact of COVID-19 on Pediatric Asthma: Practice Adjustments and Disease Burden
Papadopoulos, NG; Custovic, A; Deschildre, A; Mathioudakis, AG; Phipatanakul, W; Wong, G; Xepapadaki, P; Agache, I; Bacharier, L; Bonini, MIt is unclear whether asthma may affect susceptibility or severity of coronavirus disease 2019 (COVID-19) in children and how pediatric asthma services worldwide have responded to the pandemic.
Safety and Efficacy of Oral Fexofenadine in Children with Seasonal Allergic Rhi...
Meltzer, E; Scheinmann, P; Rosado-Pinto, J; Bachert, C; Hedlin, G; Wahn, U; Finn, A; Ruuth, EAllergic rhinitis is one of the most common clinical conditions in children; however, data regarding the safety of antihistamines in children with seasonal allergic rhinitis are limiting. To evaluate the safety and efficacy of fexofenadine in children with seasonal allergic rhinitis, data were pooled from three, double-blind, randomized, placebo-controlled, parallel-group, 2-week trials in children (6-11 year) ...
Fexofenadine is Efficacious and Safe in Children (Aged 6-11 Years) with Seasona...
Rosado-Pinto, J; Wahn, U; Meltzer, E; Finn, A; Kowalski, M; Decosta, P; Hedlin, G; Scheinmann, P; Bachert, C; Baena-Cagnani, C; Potter, P; Simons, FBackground: This is the first prospective, randomized, doubleblind, placebo-controlled study showing statistical improvement of an H1-antihistamine in children with seasonal allergic rhinitis in all symptoms throughout the entire treatment period. Objective: This randomized, placebo-controlled, parallelgroup,double-blind study was performed to assess the efficacy and safety of fexofenadine in children with seas...